在非小细胞肺癌中通过瘤微环境分析衍生CD8+T细胞透潜能剂
Michael J Topper1, Valsamo Anagnostou1,2, Kristen A Marrone1,2
1Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
iScience
|July 17, 2023
概括
表观遗传疗法可以通过增加CD8+T细胞透来提高非小细胞肺癌的免疫疗法的有效性. 这项研究将干扰素基因与免疫反应联系起来,为肺癌患者提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 对目前的免疫疗法反应有限.
- 开发新的策略来提高NSCLC的免疫疗法疗效至关重要.
研究的目的:
- 确定可增强NSCLC免疫治疗反应的生物标志物和治疗点.
- 研究表观遗传疗法可操作的干扰素基因与瘤免疫透之间的相关性.
主要方法:
- 对TCGA肺癌RNAseq数据集的分析,以将干扰素基因与免疫评分 (例如CD8A) 相关联.
- 在组织微阵列上进行免疫组织化学 (IHC) 验证,以评估CD8+T细胞透和干扰素标 (CCL5,MDA5).
- 从高级NSCLC患者的临床试验活检检查,这些患者接受了表观遗传疗法+/-免疫疗法治疗.
主要成果:
- 在干扰素基因,预测瘤免疫评分和CD8A表达之间发现了显著的相关性.
- IHC证实了CD8+T细胞透和干扰素标CCL5和MDA5.5之间的积极关联.
- 用表观遗传疗法治疗导致NSCLC患者活检中的CD8+T细胞透和CCL5染色增加.
结论:
- 表观遗传疗法可以通过促进CD8+T细胞透来增强NSCLC的抗瘤免疫力.
- 与干扰素相关的基因显示出在NSCLC中免疫治疗反应的预测生物标志物的潜力.
- 将表观遗传疗法与免疫疗法结合起来,可能是治疗NSCLC的一个有希望的策略.
相关概念视频
02:17The Tumor Microenvironment
6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
01:27Tumor Immunotherapy
567
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567